Takeda Canada Inc., the Canadian organization of Takeda Pharmaceutical Co. Ltd. (TAK) announced Wednesday that non-profit ...

NET PROFIT FORECAST: Takeda is expected to post a 59% drop in net profit to 43.58 billion yen, equivalent to $280.2 million, for the three months ended Dec. 31, according to a poll of analysts by data ...

Takeda Pharmaceutical Co. will get to arbitrate claims by a plaintiff that accused the company of delaying the generic ...

Neurocrine (NBIX) initiated a Phase 3 registrational study to evaluate the efficacy, safety and tolerability of osavampator, an investigational ...

BioMed Realty, one of the biggest labspace owners in the Boston area, recently acquired 215 First St., 150 Second St. and 11 ...

An announcement from Neurocrine ( ($NBIX) ) is now available. On January 24, 2025, Neurocrine Biosciences announced an amendment to its Exclusive ...

Brown & Brown's fourth-quarter revenue beat analyst expectations as commissions and fees rose. The insurance company said profit fell to $210 million from $269 million a year earlier, though adjusted ...

Neurocrine Biosciences amended its agreement with Takeda Pharmaceutical regarding the development and commercialization of osavampator, a treatment for major depressive disorder.

Ascentage Pharma’s U.S. IPO will support clinical testing of its two lead drugs, small molecules in development for advanced ...

Atomi Financial Group Inc. trimmed its holdings in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) ...

Harmony Biosciences' Wakix shows promise for significant revenue growth. Find out why HRMY stock’s profitability and pipeline ...

The buzz around biotech IPOs is continuing through January, with clinical-stage metabolic company Aardvark Therapeutics ...